• Home
  • Search Results
  • Is there an androgen level threshold for aneuploidy risk in infertile women?

Is there an androgen level threshold for aneuploidy risk in infertile women?

Reproductive biology and endocrinology : RB&E (2015-05-07)
Norbert Gleicher, David H McCulloh, Vitaly A Kushnir, Nandita Ganguly, David H Barad, Kara N Goldman, Mark M Kushnir, David F Albertini, James A Grifo

Low functional ovarian reserve (LFOR) has been associated with hypoandrogenemia and increased embryo aneuploidy, while androgen supplementation has been reported to improve aneuploidy rates. We, therefore, assessed whether in infertile women undergoing in vitro fertilization (IVF) androgen concentrations are associated with aneuploidy rates. This study was performed in 2 academically affiliated fertility centers in New York City and an academically affiliated steroid chemistry laboratory in Utah. Androgen concentrations were measured in blinded fashion from 84 infertile women (age 40.3+/-2.4 years) at New York University (NYU), using a validated LC-MS/MS method, in cryopreserved serum samples of patients who had undergone IVF with concomitant preimplantation genetic screening (PGS), utilizing a 24-chromosome platform. The Center for Human Reproduction (CHR) provided plasma samples of 100 historical controls (ages 38.6+/-5.0 years) undergoing IVF without PGS. Statistical comparisons were made of androgen concentrations, and of associations between androgen concentrations and embryo aneuploidy. Women undergoing IVF+PGS at NYU revealed no association between embryo aneuploidy and androgen concentrations but demonstrated significantly lower androgen concentrations than the 100 control patients from CHR, CONCLUSIONS: Though this study revealed no association between androgen levels and embryo ploidy, the extremely low androgen levels in the NYU study group raise the possibility of a threshold effect below which testosterone no longer affects aneuploidy. Before an androgen effect on embryo ploidy can be completely ruled out, a patient population with more normal androgen levels has to be investigated.

Product Number
Product Description

Luteinizing hormone releasing hormone salmon, ≥97% (HPLC)
trans-Dehydroandrosterone, ≥99%
Testosterone, ≥98%
Testosterone, purum, ≥99.0% (HPLC)
Testosterone solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
Hydroxylamine solution, 50 wt. % in H2O
Deuterium, 99.8 atom % D
Deuterium, 99.96 atom % D
Luteinizing hormone releasing hormone, ≥97% (HPLC)
Deuterium, 99.9 atom % D
Hydroxylamine solution, 50 wt. % in H2O, 99.999%
Deuterium hydride, extent of labeling: 96 mol% DH, 98 atom % D